Genomic sequencing analysis of 733 HER2-amplified Principal and metastatic breast tumours unveiled major enrichment of mutations that activate RAS–MAPK signalling in Superior tumours addressed with prior anti-HER2 therapies121. These mutations, which includes NF1 and HER2 activating mutations, add to resistance to tucatinib and neratinib. What's new in clinical innovations, research https://www.directivepublications.org/journal-of-clinical-breast-cancer/